Clinical Study of Cord Blood-derived IL-10/IL-15 CD19-CAR NK in the Treatment of Refractory/Relapsed B-cell NHL

This study is testing a new type of immune cell therapy called CAR NK cells derived from umbilical cord blood to treat aggressive or recurring B-cell lymphomas that have not responded to standard treatments. **You may be eligible if...** - You are between 18 and 75 years old - You have a confirmed diagnosis of diffuse large B-cell lymphoma (DLBCL), transformed follicular lymphoma, primary mediastinal B-cell lymphoma, mantle cell lymphoma (MCL), or another indolent B-cell lymphoma that has transformed - Your cancer came back or did not respond after at least 2 rounds of treatment (or 1 round for certain cases) - For MCL: you have already tried a BTK inhibitor drug (e.g., ibrutinib) and it failed **You may NOT be eligible if...** - You have not yet tried standard therapies - Your overall health would make this treatment unsafe - You have active infections or other serious medical conditions Talk to your doctor to see if this trial is right for you.